For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway ...

News provided by Regeneron Pharmaceuticals, Inc. Feb 16, 2024, 12:59 AM ET Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...